Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01935414
Other study ID # FKD-TEDS-001
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date August 2013
Est. completion date November 16, 2016

Study information

Verified date August 2022
Source Firstkind Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study hypothesises that the geko™ device is more efficient than TEDS in preventing the formation of symptomatic/asymptomatic Deep Vein Thrombosis (DVTs), post-surgery.


Recruitment information / eligibility

Status Completed
Enrollment 72
Est. completion date November 16, 2016
Est. primary completion date November 16, 2016
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Aged 18 years of age and over 2. Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders). 3. Has not used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator during the ten (10) days preceding enrolment. 4. Able to understand the Patient Information Sheet and willing to sign the written Informed Consent Form. 5. Able and willing to follow the protocol requirements. Exclusion Criteria: 1. Are requiring hip revision surgery 2. History or signs of previous deep or superficial vein thrombosis/pulmonary embolism. 3. Evidence of asymptomatic DVT by Duplex Ultrasound 4. Peripheral arterial disease (ABPI < 0.8), varicose veins or lower limb ulceration or ischemia. 5. Significant varicose veins, phlebitis or lower limb ulceration or ischemia. CEAP Grade 4-6. See Appendix 2 6. Recent surgery within the last 3 months (such as abdominal, gynaecological, hip or knee replacement). 7. Recent trauma to lower limb. 8. Chronic Obesity (BMI Index >40kg/m2). 9. Pregnancy. 10. Significant history of following diseases I. Cardiovascular: Recent MI (< 6 months) II. Percutaneous Coronary Intervention (PCI) with stent (< 3 months for Bare Metal Stent (BMS) and < 12 months for Drug Eluding Stent (DES) III. Moderate to severe CCF, uncontrolled AF IV. Neurological: Stroke, Hemiplegia/Paraplegia, Myopathies V. Significant dermatological conditions affecting lower limbs resulting in broken or inflamed skin particularly at the site where the device is to be fitted. VI. Clinically significant haematological conditions i.e. coagulation disorders, sickle cell disease VII. Psychiatric disorders 11. On LMWH/Heparin (Prophylactic/therapeutic doses) or Warfarin or warfarin stopped recently and replaced by LMWH/ Heparin 12. Long term steroid with dermatological changes 13. A pulse rate of less than 40 beats/minute 14. A sitting systolic blood pressure >180 and <100 mmHg and/or a sitting diastolic pressure of >100 mmHg. 15. Any significant illness during the four (4) weeks preceding the hip replacement surgery. 16. Participation in any clinical study during the eight (8) weeks preceding the screening period

Study Design


Intervention

Device:
geko™ post-surgery for 48hrs then 4hrs/day until discharge.

TEDS post-surgery for 48hrs then 4hrs/day until discharge.


Locations

Country Name City State
United Kingdom BMI The Harbour Hospital Poole Dorset

Sponsors (1)

Lead Sponsor Collaborator
Firstkind Ltd

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Presence of asymptomatic DVT assessed by Duplex Ultrasound 6 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05003843 - BOLT: Study of the Indigo® Aspiration System When Used in Patients With Deep Vein Thrombosis N/A
Recruiting NCT03937947 - Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
Withdrawn NCT04136561 - Novel Strategy to Encourage Early Removal of Central Venous Catheters N/A
Completed NCT03420625 - Blood Flow Stimulation in the Lower Limbs by Application of Different External Devices N/A
Recruiting NCT02507180 - Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
Completed NCT02555111 - Xarelto Versus no Treatment for the Prevention of Recurrent Thrombosis in Patients With Chronic Portal Vein Thrombosis. Phase 3
Terminated NCT02469376 - Evaluation of a New Imagingtechnologie for Thrombosis Phase 1
Completed NCT01975090 - The SENTRY Clinical Study N/A
Completed NCT02037607 - Incidence of Venous Thromboembolism in Children Undergoing Elective Neurosurgical Procedures N/A
Not yet recruiting NCT01357941 - Need for Antepartum Thromboprophylaxis in Pregnant Women With One Prior Episode of Venous Thromboembolism (VTE) N/A
Completed NCT00720915 - D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months N/A
Completed NCT00771303 - Ruling Out Pulmonary Embolism During Pregnancy:a Multicenter Outcome Study
Completed NCT00773448 - Screening for Occult Malignancy in Patients With Idiopathic Venous Thromboembolism N/A
Completed NCT00244725 - Odiparcil For The Prevention Of Venous Thromboembolism Phase 2
Completed NCT00264277 - D-dimer to Establish Duration of Anticoagulation After Venous Thromboembolism Phase 4
Completed NCT00365950 - 3 Months' Versus 6 Months' Anticoagulation in Patients With DVT and/or PE Phase 4
Completed NCT00182403 - Fixed Dose Heparin Study Phase 3
Completed NCT03682419 - Evaluation of Precision and Accuracy of INR Measurements in a Point of Care Device (OPTIMAL) N/A
Not yet recruiting NCT04981327 - The API-CALF Study: Apixaban to Treat Calf Vein Thrombosis Phase 3
Recruiting NCT03240120 - A Study of Dabigatran Etexilate as Primary Treatment of Malignancy Associated Venous Thromboembolism Phase 3

External Links